AIM ImmunoTech recently completed dosing of its pivotal Phase 2 DURIPANC trial combining Ampligen with durvalumab for metastatic pancreatic cancer, marking a key clinical milestone that sets the stage for upcoming data readouts and regulatory interactions. Concurrently, the company renewed its manufacturing supply agreement with Sterling Pharma Solutions, underscoring reliance on third-party production capacity that could pose operational risks. Financially, AIM extended its cash runway through multiple equity raises totaling approximately $10.4 million but faces substantial dilution pressure from nearly 48.5 million outstanding warrants. Intellectual property protections for Ampligen remain a strategic asset, supported by orphan drug designations enhancing exclusivity if regulatory approval is achieved. However, the clinical-stage biotech’s operating model hinges on successful trial progression amid capital constraints and supply chain dependencies.